Adaptive networks
Solid tumors are governed by adaptive oncogenic networks that evolve under therapeutic pressure.
Science
Why single-target therapies fail
Solid tumors are governed by adaptive oncogenic networks that evolve under therapeutic pressure. Current approaches inhibit one target, so tumors reroute and recur.
Single-target limits
Current therapies inhibit single targets without altering underlying regulatory programs.
Resistance & recurrence
Tumors reroute signaling and recur despite sequential or combination regimens.
Regulatory control needed
Modulating regulatory control is required to sensitize tumors and extend therapeutic benefit.
The Unmet Need
Patients are running out of options
Despite advances in targeted therapy and immunotherapy, treatment resistance remains the defining challenge in oncology.
Hepatocellular Carcinoma (HCC)
22%five-year relative survival across all stages
Survival falls for regional and distant-stage disease, while advanced HCC remains associated with limited treatment options.
Source: American Cancer Society / SEER DatabaseMetastatic Colorectal Cancer (CRC)
13%five-year survival for distant-stage colon cancer
Most advanced tumors eventually develop resistance to standard therapies, and pMMR/MSS disease limits immunotherapy efficacy.
Source: American Cancer Society / SEER DatabaseCHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN)
0FDA-approved treatments
Peripheral neuropathy can persist after chemotherapy, and there is currently no approved therapy to prevent or treat CIPN.
The Solution
LEAD CANDIDATE: PRX-474
Precision Locked Nucleic Acid (LNA)-Modified Antisense Oligonucleotide (ASO) Therapy
What it does
Selectively modulates microRNA activity to reprogram tumor behavior. Acts upstream of protein targets to dampen multiple oncogenic pathways simultaneously while preserving compatibility with current standard-of-care therapies.
Why it matters
Addresses resistance driven by pathway redundancy, extends durability of existing treatments, and enables combination strategies without replacing approved drugs.
What makes it different
PRX-474 has demonstrated human target engagement, a favorable Phase 1 safety profile, and preliminary anti-tumor activity, including a durable 4+ year response in metastatic colorectal cancer. It is one of only two clinically validated microRNA inhibitors in solid tumor oncology.
Novel Benefit
Preclinical and early clinical evidence suggests PRX-474 may alleviate chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect with no current FDA-approved treatment.